NPAideS: a drug-checking study among 3-methylmethcathinone (3-MMC) users.
Harm reduction journal July 28, 2023 Théo Willeman, Nathan Grundig, Christine Pochon et al. 8 citations
Between February and September 2021, a study of 45 samples from 33 people who use 3-MMC in Auvergne-Rhône-Alpes, France, found that the purity of the powder ranged from 21% to 98%. Most users were male (91%), median age 40, and regular users who bought the drug online via the Clear Web. Intravenous use was reported by 15.2% of participants. Other drugs, including 4-CEC, 4-MMC, and 2-FDCK, were also detected. Drug testing was requested by 86% of users, indicating a strong desire for harm reduction services. The data suggest that drug-checking programs can help this population.